NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

[profilepress-login id="1"]

Don't have an account? Subscribe

New online tool on diabetes awareness

By Dermot - 17th May 2017

Type 2 and pre-diabetes typically occur in midlife when lifestyle habits are well-established. Diabetes Ireland said it recognises that making changes can be difficult especially when it involves food intake and being more active. Diabetes Smart is designed with these challenges in mind, according to the organisation.

Up to 1,000 individuals receive a diagnosis of type 2 diabetes each month in Ireland. Thousands more are told by their GP to change their diet and lifestyle to help reduce their blood glucose reading and avoid acquiring type 2 diabetes. According to Diabetes Ireland: “We all need to learn the principles of healthy eating and physical activity guidelines and how to put these into practice to prevent future diabetes complications. Additionally the 200,000 people living with diabetes need regular reminding and skills updating. Diabetes Ireland took on this knowledge and skill challenge, working with Trinity College and developed Diabetes Smart, a 55-minute online series of videos, quizzes and visual tools that people can watch and participate in, from the comfort of their own homes.”

Diabetes Smart is divided into five modules that explain: diabetes (five minutes); healthy eating (20 minutes); exercise (10 minutes); diabetes medications (10 minutes); and complications (10 minutes).

“Many people want to learn at their own pace. Diabetes Smart allows people to dip in and out at their own pace thereby accumulating knowledge in bite-sizes, which will make the period of changing to a healthier lifestyle easier. You do not have to complete it all at once” commented Dr Anna Clarke, who was involved in the design and content of this project.

Dr Clarke, Health Promotion and Research Manager at Diabetes Ireland, said family members and the one million people at risk of type 2 diabetes due to poor lifestyle behaviours would benefit greatly from taking the course.

“It will empower them to be able to understand the challenge of living with diabetes and may motivate them to take proactive steps to protect their own health,” added Dr Clarke.

Diabetes Ireland said it is keen to make doctors and nurses aware of the free resource for the benefit of their patients.

Visit for further information.

<h3 class=”INTROstrapspanallMIstyles”><strong>Drug-resistant tuberculosis set to increase in four high burden countries</strong></h3> <div> <table cellspacing=”0″ cellpadding=”0″> <tbody> <tr> <td align=”left” valign=”top”>

Cases of drug-resistant tuberculosis are forecasted to increase in four high burden countries (India, the Philippines, Russia, and South Africa) between 2000 and 2040. The upturn is likely to be as a result of increased transmission of drug-resistant tuberculosis between people, rather than by strains that acquire resistance to anti-tuberculosis drugs, according to a study published in <em>The Lancet Infectious Diseases</em>.

</td> </tr> </tbody> </table> </div>

 While better access to treatment programmes will reduce rates of drug-resistant tuberculosis in countries with a high burden, they will not eradicate the problem alone and current efforts may not be enough to reverse the epidemic.

As a result, research into additional control measures will be needed to prevent drug-resistant tuberculosis spreading between people. To reduce the burden of drug-resistant disease, the researchers recommend that treatment be coupled with ways to prevent spread, such as early detection, reducing the number of patients who do not complete treatment and providing tailored treatment depending on which drugs the strain is susceptible to.

“This study uses a complex model bringing together the best available data from multiple sources in four countries hit hard by the drug-resistant tuberculosis epidemic. Our findings show that drug-resistant tuberculosis cases in these countries are expected to rise over the next two decades and that fewer cases over time will be caused by acquired drug resistance during tuberculosis treatment. These findings suggest that person-to-person transmission will become the engine that drives drug-resistant tuberculosis in these countries,” said Dr Aditya Sharma, US Centers for Disease Control and Prevention (CDC), US.

Latest figures estimate that each year there are 10.4 million new cases of tuberculosis, leading to 1.8 million deaths globally. Nearly 40 per cent of all drug-resistant tuberculosis cases occur in Russia, India, the Philippines and South Africa – accounting for more than 230,000 cases of drug-resistant disease in 2015.

 Tuberculosis is a bacterial disease that can be treated with a combination of antibiotic drugs. However, as a result of use and misuse of antibiotics (such as using the wrong drug, or not completing the full course of treatment) bacteria can develop drug resistance.

There are two forms of drug-resistant tuberculosis important to public health – multidrug-resistant tuberculosis is resistant to more than one of the first-line drugs for the disease, whereas extensively drug-resistant tuberculosis is additionally resistant to fluoroquinolones and at least one of the second-line injectable tuberculosis drugs.

Treating extensively drug-resistant tuberculosis takes up to two years with toxic drugs, including daily injections that can have severe long-term side effects (eg, hearing loss, psychosis). Around 40 per cent of people diagnosed with multidrug-resistant tuberculosis die of the disease, compared with 60 per cent of those with extensively drug-resistant tuberculosis.

The study is based on a mathematical model that forecasts how tuberculosis is likely to progress in the four most-affected countries. It uses data from the World Health Organisation (WHO) and surveys estimating the number of drug-resistant tuberculosis cases to predict how many cases of multidrug-resistant and extensively drug-resistant tuberculosis would develop during 2000 and 2040. It also estimates how many of these would be as a result of non-resistant strains acquiring resistance during treatment.

 The model estimates that cases of both forms of drug-resistant disease will increase, suggesting that almost a third of tuberculosis cases in Russia (32.5 per cent) would be multidrug-resistant by 2040, as well as 12.4 per cent of tuberculosis cases in India, 8.9 per cent in the Philippines, and 5.7 per cent in South Africa. This compares to almost a quarter of cases (24.8 per cent) in Russia, 7.9 per cent in India, 6 per cent in the Philippines, and 2.5 per cent in South Africa in 2000.

In addition, almost one-in-10 cases of multi drug-resistant tuberculosis in each of the four countries were expected to be extensively drug-resistant by 2040 (9 per cent in Russia and the Philippines, 8.9 per cent in India, and 8.5 per cent in South Africa), compared with around 1 per cent in 2000 (1.3 per cent in Russia, 1.6 per cent in the Philippines, 0.9 per cent in India, and 0.4 per cent in South Africa).

The study predicts that fewer cases of drug-resistant tuberculosis will be caused by strains acquiring resistance – reducing from around 30 per cent of cases of multidrug-resistant tuberculosis in 2000 to 20-25 per cent in 2040, and 80 per cent of cases of extensively drug-resistant disease in 2000, to 50 per cent in 2040.

The authors propose that increased spread from person to person will be responsible for the growing number of drug-resistant tuberculosis cases.

“We cannot focus solely on curing people with tuberculosis or drug-resistant tuberculosis if we want to halt the epidemic. Even if we prevent new drug-resistant infections, there are enough current cases to keep the epidemic going, and drug-resistant tuberculosis will continue to be an increasingly dangerous threat so long as resistant strains spread through the air from one person to another,” said Dr Sharma. “We need to dramatically step up efforts to break the cycle of transmission – while also maintaining work to rapidly find and treat all people with tuberculosis. We must strengthen infection control measures, focus on households, health centres and communities to prevent tuberculosis spreading from person to person and develop more effective diagnostic tests to rapidly and accurately detect drug resistance.”

The authors note that, although their model is based on the best available data, the data for Russia and India was scaled up from regional data and may not represent the true national disease burden. The model does also not take into account population density and migration, which could increase the transmission rates.

Writing in a linked Comment, Prof Andrei Mariandyshev, Northern State Medical University, Russia, said: “WHO’s End TB strategy sets targets to eliminate tuberculosis at a global level. According to this strategy, a 95 per cent reduction in the number of deaths from tuberculosis and a 90 per cent reduction in the incidence of tuberculosis should be achieved by 2035, compared with 2015. An important component of the road map for the elimination of tuberculosis is preventing the spread of drug-resistant tuberculosis, especially in the 30 countries with the highest burden of tuberculosis…. The most important measure that might help to prevent the spread of drug-resistant tuberculosis is the implementation of short-course regimens of chemotherapy for patients with multidrug-resistant tuberculosis. Introduction of nine to 12 month courses of multidrug-resistant tuberculosis therapy will increase the effectiveness of treatment and reduce the total number of anti-tuberculosis drugs during the course of treatment and save funds that can be used to treat more patients. The use of new drugs that correspond with WHO recommendations will improve the quality of treatment for adults and children with drug-resistant tuberculosis and will help to eliminate tuberculosis globally.”

Leave a Reply

Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read